XML 35 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 212 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Operating activities:      
Net loss $ (4,869) $ (3,082) $ (281,757)
Adjustments to reconcile net loss to net cash used in operating activities:      
Accretion of interest on notes payable, net of amortization of debt premium     100
Amortization of investment premiums, net     (2,297)
Change in valuation of liabilities measured at fair value   (570) (7,475)
Change in valuation of financial instruments associated with stock purchase agreement 47   568
Depreciation 23 26 12,708
Amortization of intangible assets     886
Fixed asset impairment     221
Unrealized foreign exchange (gains) losses     7,747
Deferred revenue     (98)
Compensation for warrants issued to non-employees     1,215
Gain on sale of patents     (5,500)
Shares issued for IP rights     446
Loss (gain) on disposal of property, plant and equipment     38
Goodwill and intangibles impairment     7,934
Stock-based compensation 187 72 19,947
Provision for restructuring     1,779
Amortization of issuance costs of Preferred Ordinary 'C' shares     2,517
Transaction costs on sale of Economic Rights     33
Gain on termination of distribution agreements     (1,192)
Changes in operating assets and liabilities:      
Prepaid expenses and other assets (1,360) (482) (2,858)
Accounts payable and other current liabilities 1,246 (1,332) (3,049)
Net cash used in operating activities (4,726) (5,368) (248,087)
Investing activities:      
Purchase of ALIGN     (3,763)
Purchase of property, plant and equipment (31) (92) (9,088)
Minimum royalty payments received from termination of ALIGN license agreement 96 132 492
Proceeds from sale of patents     5,500
Proceeds from sale of property, plant and equipment     225
Purchase of short-term investments on deposit, net of maturities     (156,657)
Cash proceeds from redemption of short term securities     162,729
Net cash provided by (used in) investing activities 65 40 (562)
Financing activities:      
Payments of capital lease obligations     (3,719)
Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs     121,678
Proceeds from issuance of common stock and warrants, net of issuance costs 1,676 3,414 124,865
Proceeds from the exercise of stock options and warrants, net of issuance costs     267
Payment of preferred stock dividend (50) (129) (2,253)
Repayment of government loan     (455)
Government loan received     414
Loan received from Cyclacel Group plc     9,103
Proceeds of committable loan notes issued from shareholders     8,883
Loans received from shareholders     1,645
Cash and cash equivalents assumed on stock purchase of Xcyte     17,915
Costs associated with stock purchase     (1,951)
Net cash provided by financing activities 1,626 3,285 276,392
Effect of exchange rate changes on cash and cash equivalents 43 (230) 411
Net (decrease) increase in cash and cash equivalents (2,992) (2,273) 28,154
Cash and cash equivalents, beginning of period 31,146 16,412  
Cash and cash equivalents, end of period 28,154 14,139 28,154
Cash received during the period for:      
Interest 1 1 11,769
Taxes     19,742
Cash paid during the period for:      
Taxes 25   25
Interest     (1,914)
Schedule of non-cash transactions:      
Acquisitions of equipment purchased through capital leases     3,470
Issuance of shares of common stock in connection with license agreements     592
Issuance of Ordinary shares on conversion of bridging loan     1,638
Issuance of Preferred Ordinary 'C' shares on conversion of secured convertible loan notes and accrued interest     8,893
Issuance of Ordinary shares in lieu of cash bonus   181 345
Issuance of other long term payable on ALIGN acquisition     $ 1,122